GLP1R and diabetic kidney disease: SGLT2i and GLP-1 RA are both included in subspecialty guidelines as evidence-based therapies for the management of people with diabetic kidney disease [36,47], and ongoing studies are evaluating their impact in non-diabetic and non-proteinuric kidney disease.